Last updated: February 19, 2026
This report analyzes Russian Federation patent RU2018146504, focusing on its claims related to a specific crystalline form of tiotropium bromide. The patent's scope and the surrounding patent landscape are examined to inform R&D and investment decisions within the pharmaceutical industry.
What is the Core Innovation Claimed in RU2018146504?
Patent RU2018146504, filed by BIOLambda Ltd. on December 24, 2018, and published on May 29, 2020, claims a specific crystalline form of tiotropium bromide, designated as "Form A." This form is characterized by distinct physicochemical properties, including its X-ray powder diffraction (XRPD) pattern, infrared (IR) spectrum, and differential scanning calorimetry (DSC) profile.
What are the Key Characteristics of Tiotropium Bromide Form A?
The patent defines Form A by its unique spectroscopic and thermal signatures. These include:
- X-ray Powder Diffraction (XRPD) Pattern: The patent provides a list of characteristic diffraction angles (2θ) and their relative intensities for Form A. Specific d-spacings and intensities are critical for distinguishing this form from other crystalline or amorphous states. For example, significant peaks are listed at approximately 6.2°, 10.1°, 12.4°, 15.8°, 19.4°, and 24.1° (± 0.2° 2θ).
- Infrared (IR) Spectrum: The patent specifies characteristic absorption bands in the IR spectrum. These bands correspond to specific molecular vibrations within the crystal lattice and functional groups of tiotropium bromide. Key absorption bands are identified in wavenumbers (cm⁻¹), such as those around 3000-2800, 1600-1500, 1300-1100, and below 900 cm⁻¹.
- Differential Scanning Calorimetry (DSC) Profile: Form A exhibits a distinct thermal event, typically a melting point or decomposition onset, at a specific temperature range. The patent indicates a melting endotherm with a peak maximum around 250°C to 260°C, often accompanied by decomposition.
- Thermogravimetric Analysis (TGA): TGA data reveals the thermal stability and potential presence of solvates or hydrates, indicating minimal weight loss below a certain temperature range, signifying its anhydrous or low-solvated state.
What is the Significance of Tiotropium Bromide Form A?
The claimed crystalline form is presented as having improved properties relevant to pharmaceutical formulation and efficacy. These potential advantages could include:
- Enhanced Stability: Crystalline forms often exhibit greater chemical and physical stability compared to amorphous forms or other polymorphs, leading to longer shelf life and consistent drug product quality.
- Improved Solubility and Dissolution Rate: While specific comparative data is not detailed in the patent claims, novel crystalline forms can be engineered to optimize solubility and dissolution profiles, which are critical for bioavailability and therapeutic effectiveness.
- Processability: A particular crystalline form may offer better handling characteristics during manufacturing, such as flowability and compressibility, simplifying downstream processing into finished dosage forms.
- Patentability: The novelty of a specific crystalline form provides a basis for securing new intellectual property protection, even for an established active pharmaceutical ingredient (API) like tiotropium bromide.
What is the Scope of the Patent Claims?
The claims of RU2018146504 are narrowly focused on the specific crystalline Form A of tiotropium bromide.
Claim 1: The Crystallin Form
Claim 1 is the primary independent claim and defines tiotropium bromide characterized by its XRPD pattern. It specifies a crystalline form of tiotropium bromide exhibiting characteristic peaks at specific 2θ angles as listed in the patent. This claim directly protects the novel crystalline structure itself.
Claim 2-5: Characterization Data
Dependent claims further define Form A by its IR spectrum and DSC profile. These claims reinforce the characterization of the claimed crystalline form by providing additional distinguishing analytical data, making the patent more robust against challenges based solely on XRPD.
Claim 6: Pharmaceutical Composition
Claim 6 extends the protection to pharmaceutical compositions containing the claimed crystalline form of tiotropium bromide. This broadens the patent's scope to include drug products formulated with the novel polymorph.
Claim 7: Use of the Pharmaceutical Composition
Claim 7 covers the use of the pharmaceutical composition for the treatment of respiratory diseases, specifically chronic obstructive pulmonary disease (COPD) and asthma. This claim protects the therapeutic application of the invention.
Claim 8: Method of Treatment
Claim 8 defines a method of treating COPD and asthma by administering a therapeutically effective amount of the pharmaceutical composition. This method-of-treatment claim offers an additional layer of protection.
What is the Patent Landscape for Tiotropium Bromide Polymorphs?
The patent landscape for tiotropium bromide is extensive, reflecting its established therapeutic value, particularly in the treatment of COPD. Several patents exist globally that claim different crystalline forms, synthesis methods, and pharmaceutical compositions.
Prior Art Polymorphs
Tiotropium bromide is known to exhibit various crystalline forms, each with distinct physicochemical properties. Pharmaceutical companies have previously patented several of these polymorphs. For example:
- WO2004031166 (Boehringer Ingelheim): This patent family, which is foundational for tiotropium bromide's original market exclusivity, disclosed and claimed various crystalline forms of tiotropium bromide, including anhydrous forms and solvates. These early patents established significant intellectual property around the compound.
- US7045513 B2 (Boehringer Ingelheim): This U.S. patent, related to the above WO application, claims specific crystalline forms and pharmaceutical compositions containing tiotropium bromide.
- CN101347871A (Shenyang Pharmaceutical University): This Chinese patent application describes a crystalline form of tiotropium bromide and its preparation method.
RU2018146504's Position
RU2018146504 appears to claim a specific crystalline form that is potentially distinct from those previously disclosed and patented. The novelty and inventive step of Form A would be assessed against the existing body of prior art, including the polymorphs described in the patents mentioned above. The success of this patent hinges on demonstrating that Form A possesses characteristics that are not obvious from existing knowledge and that offer tangible advantages.
Key Competitors and Their Patent Strategies
Major pharmaceutical companies involved in the development and marketing of tiotropium bromide, such as Boehringer Ingelheim (the originator), have historically secured broad patent protection covering the compound, its various forms, and its therapeutic uses.
- Boehringer Ingelheim: Holds the foundational patents for tiotropium bromide (Spiriva®). Their patent strategy has focused on protecting the original compound, key polymorphs, specific formulations (e.g., dry powder inhalers), and methods of use.
- Generic Manufacturers: As patents expire, generic manufacturers seek to develop and patent alternative crystalline forms, improved formulations, or novel delivery systems to enter the market. These strategies often involve identifying polymorphic forms that were not covered by the originator's patents or developing bioequivalent generic versions.
Analysis of Potential Infringement
For a company developing or marketing tiotropium bromide, a thorough freedom-to-operate (FTO) analysis is critical. This involves:
- Identifying Overlapping Claims: Assessing whether any proposed product or process falls within the scope of RU2018146504's claims, particularly claims related to Form A and compositions containing it.
- Differentiating Polymorphs: If a company is developing a new crystalline form, rigorous analytical characterization is required to demonstrate its distinctness from Form A. This involves comparing XRPD, IR, and DSC data.
- Formulation and Manufacturing: Even if a different crystalline form is used, patent claims related to pharmaceutical compositions and methods of treatment still need to be considered.
The specific XRPD peaks, IR absorption bands, and DSC profiles provided in RU2018146504 are crucial for determining potential infringement. Any crystalline tiotropium bromide exhibiting a statistically significant overlap with these characteristic parameters could be considered infringing.
What are the Implications for R&D and Investment?
The existence of RU2018146504 influences R&D strategies and investment decisions in several ways:
R&D Strategy
- Polymorph Screening: Companies researching novel tiotropium bromide formulations or seeking to develop generic versions must include comprehensive polymorph screening as a critical part of their R&D process. This ensures that any newly developed crystalline form is indeed novel and does not infringe on existing patents like RU2018146504.
- Characterization Expertise: Developing and asserting patents for novel polymorphic forms requires robust analytical capabilities. Investment in advanced analytical instrumentation and skilled personnel for solid-state characterization is essential.
- Lifecycle Management: For originator companies, identifying and patenting novel, advantageous polymorphic forms is a key strategy for extending the commercial lifecycle of a drug beyond the expiry of initial composition-of-matter patents.
Investment Decisions
- Market Entry Barriers: RU2018146504, and similar patents for novel polymorphs, can create significant barriers to entry for generic manufacturers. Investors need to assess the strength and breadth of these patent protections when evaluating companies in the tiotropium bromide market.
- Intellectual Property Portfolio Value: The value of a company's intellectual property portfolio is a critical factor in investment decisions. Patents like RU2018146504 contribute to the overall IP strength, potentially increasing a company's valuation and market position.
- Risk Assessment: Investors should consider the litigation risk associated with pharmaceutical patents. The presence of a patent for a specific crystalline form necessitates careful due diligence to avoid potential infringement claims.
Key Takeaways
- RU2018146504 claims a novel crystalline form of tiotropium bromide, designated "Form A," characterized by specific XRPD, IR, and DSC profiles.
- The patent also covers pharmaceutical compositions containing Form A and its use in treating COPD and asthma.
- The patent landscape for tiotropium bromide is dense, with multiple patents existing for various crystalline forms and formulations, primarily held by originator companies like Boehringer Ingelheim.
- RU2018146504 adds to the complexity of this landscape, potentially restricting the development and commercialization of specific tiotropium bromide crystalline forms.
- Companies seeking to develop or invest in tiotropium bromide-related products must conduct thorough polymorph screening and freedom-to-operate analyses to navigate existing intellectual property.
Frequently Asked Questions
-
How does Form A claimed in RU2018146504 differ from previously patented polymorphs of tiotropium bromide?
The patent asserts novelty based on a unique combination of XRPD, IR, and DSC characteristics. A definitive comparison requires direct analytical data against established prior art polymorphs detailed in other patents.
-
What are the potential advantages of tiotropium bromide Form A over other known crystalline forms?
While not explicitly quantified in the claims, potential advantages typically associated with novel crystalline forms include improved stability, enhanced solubility, and better manufacturing processability.
-
Is tiotropium bromide Form A suitable for use in dry powder inhalers (DPIs)?
The patent claims pharmaceutical compositions for treating respiratory diseases, implying suitability for inhalation. The specific physical properties of Form A would determine its efficacy and performance in DPI formulations.
-
What is the expiration date of patent RU2018146504?
As a Russian Federation patent filed in December 2018, its standard term is 20 years from the filing date, subject to potential extensions for pharmaceutical products and specific national regulations.
-
Can generic manufacturers develop tiotropium bromide products if RU2018146504 is in force?
Generic manufacturers can develop tiotropium bromide products if their crystalline form and/or formulation do not infringe on the claims of RU2018146504. This necessitates the development of a distinct, non-infringing polymorphic form or formulation.
Cited Sources
[1] BIOLambda Ltd. (2020). RU2018146504: Crystalline form of tiotropium bromide. Russian Federation Patent.
[2] Boehringer Ingelheim. (2004). WO2004031166: Tiotropium bromide crystalline forms. International Patent Application.
[3] Boehringer Ingelheim. (2006). US7045513 B2: Tiotropium bromide crystalline forms. United States Patent.
[4] Shenyang Pharmaceutical University. (2009). CN101347871A: Crystalline form of tiotropium bromide and preparation method. Chinese Patent Application.
